Finally, we evaluated the correlation between ctDNA levels and metabolic tumour burden (MTB) prior to treatment and at the time progression in a subgroup of patients treated with BRAF/MEK inhibitors (N = 15). This evidence concerns the gene MAP2K7 and neoplasm.